Response Evaluation Criteria in Solid Tumors (RECIST)
Definitions
Response criteria published in 2000
Updated WHO criteria
Designed to minimize risk of measurement error and prevent overestimation of response rates
Rationale and Key Concepts
Patient eligibility
Patients with measurable disease at baseline
Measurable disease: Indicates presence of at least 1 measurable lesion
Enrolled in protocols where objective tumor response is primary endpoint
Assess disease at baseline
Evaluate for measurable disease
Identify target and nontarget lesions
Measure target lesions
Tumor burden: Sum of target lesions
Assess disease at follow-up
Measure target lesions
Assess nontarget lesions
Identify new lesions
Calculate time point response
IMAGING ANATOMY
Measurable and Nonmeasurable Disease
Baseline Documentation
Methods of Assessment
Summary of Minimum Size Requirements for Measurable Lesions
CLINICAL IMPLICATIONS
Evaluation of Target Lesions
Evaluation of Nontarget Lesions
Evaluation of Best Overall Response
Confirmation of Response
Selected References
Gehan EA et al: Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst. 92(3):179-81, 2000
Kusaba H et al: A summary report of response evaluation criteria in solid tumors (RECIST criteria). Gan To Kagaku Ryoho. 27(1):1-5, 2000
Therasse P et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92(3):205-16, 2000
Related Anatomy
Loading...
Related Differential Diagnoses
Loading...
References
Tables
Tables
KEY FACTS
Terminology
Baseline Evaluation
Clinical Implications
TERMINOLOGY
Abbreviations
Response Evaluation Criteria in Solid Tumors (RECIST)
Definitions
Response criteria published in 2000
Updated WHO criteria
Designed to minimize risk of measurement error and prevent overestimation of response rates
Rationale and Key Concepts
Patient eligibility
Patients with measurable disease at baseline
Measurable disease: Indicates presence of at least 1 measurable lesion
Enrolled in protocols where objective tumor response is primary endpoint
Assess disease at baseline
Evaluate for measurable disease
Identify target and nontarget lesions
Measure target lesions
Tumor burden: Sum of target lesions
Assess disease at follow-up
Measure target lesions
Assess nontarget lesions
Identify new lesions
Calculate time point response
IMAGING ANATOMY
Measurable and Nonmeasurable Disease
Baseline Documentation
Methods of Assessment
Summary of Minimum Size Requirements for Measurable Lesions
CLINICAL IMPLICATIONS
Evaluation of Target Lesions
Evaluation of Nontarget Lesions
Evaluation of Best Overall Response
Confirmation of Response
Selected References
Gehan EA et al: Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst. 92(3):179-81, 2000
Kusaba H et al: A summary report of response evaluation criteria in solid tumors (RECIST criteria). Gan To Kagaku Ryoho. 27(1):1-5, 2000
Therasse P et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92(3):205-16, 2000
STATdx includes over 200,000 searchable images, including x-ray, CT, MR, and ultrasound images. To access all images, please log in or subscribe.